The primary objective of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid. One dose of 500 mg nicotinic acid will be used (in addition to placebo) to build a dose response curve for this compound in human cerebrospinal fluid. This objective will demonstrate target engagement of HCAR2 in the CNS after oral treatment with niacin. The primary endpoints are to show increased nicotinic acid levels in blood and CSF.THIS STUDY IS ENROLLING - Methods of recruitment include personal contact, database searches, (Registry IRB# 1010002668), review of medical records, identifying potential subjects who meet study criteria. Recruitment will primarily happen in Adult Neurology Clinic through Dr. Brosch’s clinical patients.

The purpose of this study is to establish a recruitment database of individuals who have contacted the research staff in the department of dermatology expressing interest in participating in clinical research and requesting to be contacted if eligible to participate.

Kids and teens with asthma often get less physical activity than recommended, even though exercise can improve asthma symptoms, lung function, overall fitness, and mental health. But we don’t fully understand: • How active our own clinic’s patients actually are • What they think about exercise • What gets in the way • What kinds of at home exercise options they might be interested in This study aims to fill those gaps so the clinic can better support families in building healthy activity habits.THIS STUDY IS ENROLLING BY INVITATION ONLY - Participants will be approached during a regularly scheduled pulmonology clinic visit and, if interested, will participate in the consent/assent discussion.

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Primary ObjectiveTo compare the progression-free survival (PFS) as assessed by blinded Independent. Radiological Review Committee (IRRC) based on Response Evaluation Criteria in. Solid Tumors (RECIST) v1.1, of ivonescimab in combination with modified 5-FU, oxaliplatin, and leucovorin (mFOLFOX6) to bevacizumab in combination with mFOLFOX6.Secondary ObjectivesTo compare the overall survival (OS) of ivonescimab in combination with mFOLFOX6 to bevacizumab in combination with mFOLFOX6. To compare objective response rate (ORR) and duration of response (DOR) as assessed by blinded IRRC based on RECIST v1.1, of ivonescimab in combination with mFOLFOX6 to bevacizumab plus mFOLFOX6. To compare the safety and tolerability of ivonescimab in combination with mFOLFOX6 to bevacizumab in combination with mFOLFOX6. To evaluate the pharmacokinetic (PK) profile of ivonescimab in combination with mFOLFOX6. To evaluate the immunogenicity of ivonescimab in combination with mFOLFOX6.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Circulating tumor DNA (ctDNA) is a biomarker that shows how well the body responds to treatment for a disease. Blood and tissue specimens will be collected from patients to find out whether ctDNA can be detected in those specimens so that tools can be developed to predict the presence (or absence) of ctDNA after cancer treatment.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632